pharma · Microcystic Lymphatic Malformation · Pachyonychia Congenita · PVLA
PALVELLA THERAPEUTICS
PALVELLA THERAPEUTICS, INC.
PALVELLA THERAPEUTICS patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Wayne, USA
- Founded
- 2015
- Employees
- 38
- Programs
- 7
- Drugs
- 0
- Patents
- 9
PALVELLA THERAPEUTICS patents
9 pharmaceutical patents indexed for PALVELLA THERAPEUTICS. 0 expire within 24 months.
PALVELLA THERAPEUTICS has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12329748
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 12268673
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11679101
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11617742
Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
granted -
US 11135204
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11000513
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 10722499
Anyhydrous compositions of mTOR inhibitors and methods of use
granted -
US 10172789
Compositions for transdermal delivery of mTOR inhibitors
granted -
US 9855252
Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
granted
Frequently asked questions
How many patents does PALVELLA THERAPEUTICS have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do PALVELLA THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.